BZYR (Burzynski Research Institute) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


What is Burzynski Research Institute Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Burzynski Research Institute's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BZYR vs CLSDQ, ZVSA, ADAPY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Burzynski Research Institute's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burzynski Research Institute Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Margin of Safety % (DCF Earnings Based) falls into.


Burzynski Research Institute Business Description

Address 9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.